根据本周将在 2018 年发表的研究，两种免疫检查点抑制剂 Imfinzi（durvalumab）和 Tremelimumab 的组合提高了晚期肝癌患者的总生存期，而 Imfinzi 加化疗延长了胆道癌患者的生存期。 2022 年 ASCO 胃肠癌研讨会。 另一项试验表明，Keytruda（pembrolizumab）也提高了肝癌患者的生存率。
Immunotherapy Improves Survival for People With Liver Cancer
Three checkpoint inhibitors reduce the risk of death for patients with hard-to-treat liver and biliary tract cancers.
January 20, 2022 • By Liz Highleyman
Share
Comments
Print
A combination of two immune checkpoint inhibitors, Imfinzi (durvalumab) and tremelimumab, led to improved overall survival for people with advanced liver cancer, while Imfinzi plus chemotherapy prolonged survival for those with biliary tract cancer, according to studies to be presented this week at the 2022 ASCO Gastrointestinal Cancers Symposium. Another trial showed that Keytruda (pembrolizumab) also improved survival for liver cancer patients.